Compare SGRP & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | AYTU |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 23.4M |
| IPO Year | 1996 | N/A |
| Metric | SGRP | AYTU |
|---|---|---|
| Price | $0.82 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 67.6K | ★ 135.0K |
| Earning Date | 11-14-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $147,130,000.00 | $63,696,000.00 |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.79 | N/A |
| 52 Week Low | $0.76 | $0.95 |
| 52 Week High | $2.10 | $3.07 |
| Indicator | SGRP | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 56.52 |
| Support Level | $0.77 | $2.60 |
| Resistance Level | $0.92 | $2.87 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 41.92 | 34.23 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.